Drug Profile
Resamirigene bilparvovec - Astellas Gene Therapies
Alternative Names: AT-001 - Astellas Gene Therapies/Genethon; AT-132; Resamirigene bilparvovecLatest Information Update: 21 Nov 2023
Price :
$50
*
At a glance
- Originator Audentes Therapeutics; Genethon
- Developer Astellas Gene Therapies
- Class Gene therapies
- Mechanism of Action Gene transference; Myotubularin expression stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Congenital structural myopathies
Most Recent Events
- 15 Nov 2023 Efficacy and adverse event data from the phase I/II/III ASPIRO trial in congenital structural myopathies released by Astellas Pharma
- 06 Feb 2023 Astellas Pharma announced that it expects the reinitiation of the ASPIRO trial in 2024
- 30 Nov 2022 Astellas Pharma conducted a PRIME meeting with the EMA regarding the clinical hold for the ASPIRO trial